|
|
Background:
Treatment of chronic myeloid leukemia (CML) has experienced dramatic changes in the most recent decade. Analyzing the atomic pathways that prompt the advancement of this infection brought about the improvement of focused treatment against the sub-atomic driver of CML, to be specific the aberrantly activated tyrosine kinase BCR-ABL1. Dasatinib has shown tough clinical reactions in patients, both as first-line and ensuing lines of treatment. We examined the hazard elements and administration of pleural emission related with dasatinib treatment for chronic myelogenous leukemia (CML) after failure of imatinib. Materials and Methods: 270 patients with imatinib resistant/ - intolerant CML in chronic stage (CML-CP) got dasatinib 100mg once every day, 50mg twice daily, 140mg once daily, or 70 mg twice daily. We analysed patients with CML treated with dasatinib for 3 years for the development of pleural effusion. Result: Pleural effusion happened in 32 patients, including 24% of those treated in chronic stage (CP), 46% in accelerated stage (AP), and 29% in blast stage (BP). By examination, history of heart illness, hypertension, and utilization of a twice-every day plan were recognized as variables related with occurrence of pleural effusions. Effusions were exudative in 67% of the assessable cases. In a few patients, effusions were related with reversible additions of right ventricular systolic pressure. Conclusion: Pleural emanations happen amid dasatinib treatment, especially among patients in AP or BP. A twice-day by day schedule may bring about a higher frequency of pleural effusion. Close checking and opportune mediation may enable patients to proceed with treatment and accomplish the coveted clinical advantage.
Keywords: Dasatinib, imatinib, TKI, chronic myeloid leukaemia, autoimmunity, toxicity, pleural effusions.
Corresponding Author: Dr. Vivek Agarwal, Associate Professor, Department of General Medicine, Mayo Institute of Medical Sciences, Gadia, Barabanki, Uttar Pradesh, India
This article may be cited as: Kumar V, Agarwal V. Investigations of Risk Factors and Management of Pleural Effusion associated with Dasatinib Therapy for Chronic Myelogenous Leukemia after Imatinib Failure. J Adv Med Dent Scie Res 2014;2(3):224-227.
|
